Savara Q1 2025 Earnings Report

Savara EPS Results

• Actual EPS: -$0.14
• Consensus EPS: -$0.12
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

Savara Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Savara Announcement Details

• Quarter: Q1 2025
• Date: 8/13/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Savara (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs. Savara has evaluated molgramostim in clinical trials for aPAP and has pursued regulatory approval in the United States and other markets.

The company was established as a specialty pharmaceutical business and later shifted its strategy toward rare respiratory diseases, including through its acquisition of Parion Sciences’ respiratory drug development programs. Savara is headquartered in Austin, Texas, and conducts development activities through clinical and regulatory programs in the United States and internationally. Matthew Pauls has served as the company’s president and chief executive officer.